APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome

Trial Profile

APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Asunercept (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Apogenix
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Dec 2016 Results published in the Media Release
    • 05 Dec 2016 According to an Apogenix media release, results presented at ASH meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top